Related Experiment Videos
Granulocyte-colony stimulating factor for sulfasalazine-induced agranulocytosis
1Department of Pharmacy Practice, School of Pharmacy, Southwestern Oklahoma State University, Weatherford.
Objective:
To report a case of sulfasalazine-induced agranulocytosis that was successfully treated with granulocyte-colony stimulating factor (G-CSF).
Case Summary:
An 82-year-old woman developed agranulocytosis within two months of initiating sulfasalazine therapy. She was hospitalized, empiric antibiotic and antifungal agents were prescribed, and sulfasalazine therapy was stopped. The patient received G-CSF 600 micrograms/d subcutaneously for six consecutive days, starting on hospital day 5. Agranulocytosis resolved on day 5 and leukopenia on day 6 of G-CSF therapy. No adverse reactions were attributed to administration of this agent and the patient was discharged on hospital day 13.
Discussion:
Numerous agents, including sulfasalazine, have been associated with agranulocytosis. Agranulocytic patients frequently experience life-threatening bacterial and fungal infections. Administration of colony stimulating factors may reduce the duration of agranulocytosis and incidence of life-threatening infections.
Conclusions:
G-CSF administration appears to have decreased the duration of this elderly patient's agranulocytosis and hospitalization.